Medtronic has announced that its MiniMed 780G system, featuring expanded SmartGuard technology, has received the CE Mark, allowing its commercial launch across Europe. The system is designed to automate insulin delivery for people with type 1 diabetes, aiming to improve glucose control and reduce the burden of daily diabetes management.

The MiniMed 780G system includes enhancements such as automatic correction boluses and an adjustable target glucose setting, providing users with greater flexibility and personalization in their diabetes care. The CE Mark approval follows clinical studies demonstrating the system's safety and effectiveness in managing blood glucose levels.

This regulatory milestone enables Medtronic to offer the MiniMed 780G system to healthcare professionals and patients in European markets, supporting improved diabetes management outcomes. For more information, visit Medtronic's official announcement.